How New Drugs Are Innovating Chronic Graft-Versus-Host Disease Treatment
Chronic graft-versus-host disease (GVHD) remains a challenging complication post-stem cell transplant, but recent advancements in treatment are reshaping this landscape. New FDA-approved drugs such as ibrutinib, ruxolitinib, belumosudil, and axatilimab offer targeted therapies that promise improved quality of life with fewer side effects compared to traditional steroids. These developments are crucial as they introduce novel […]
3 minute read